Accumulating evidence has established that SARS-CoV-2 elicits weaker induction of type 1 IFNs when compared to other respiratory viruses74 and is marked by comparatively less responsive IL-1 and NLRP3 inflammasome pathways in early or non-severe COVID-19 patients75. The gene discussed is NLRP3; the disease is COVID-19.